Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 7/20 | 0.51 |
| ▸ | FNTB | P49356 | 7/20 | 0.51 |
| ▸ | PGGT1B | P53609 | 6/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.46 |
| ▸ | TERT | O14746 | 1/20 | 0.44 |
| ▸ | GSR | P00390 | 1/20 | 0.42 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.41 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.41 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.40 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.40 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2887196 | 0.90 | TERT (0.52) | FOLH1SLC6A5TERTGSRCPB2 | |
| SCHEMBL2887200 | 0.90 | TERT (0.52) | FOLH1SLC6A5TERTGSRCPB2 | |
| SCHEMBL23968643 | 0.90 | PTGS1 (0.54) | FNTAFNTBPGGT1BPTGS1GSTK1 | |
| SCHEMBL29369655 | 0.90 | PTGS1 (0.54) | FNTAFNTBPGGT1BPTGS1GSTK1 | |
| SCHEMBL30957279 | 0.89 | PTGS1 (0.50) | FNTAFNTBPGGT1BPTGS1GSTK1 | |
| SCHEMBL30828464 | 0.88 | FOLH1 (0.48) | FNTAFNTBPGGT1BPTGS1GSTK1 | |
| SCHEMBL29915442 | 0.88 | TERT (0.50) | FOLH1SLC6A5TERTGSRCPB2 | |
| SCHEMBL29286382 | 0.86 | FOLH1 (0.50) | PTGS1GSTK1FOLH1SLC6A5TERT | |
| SCHEMBL29286384 | 0.86 | FOLH1 (0.50) | PTGS1GSTK1FOLH1SLC6A5TERT | |
| SCHEMBL21190713 | 0.86 | NOD1 (0.50) | FNTAFNTBPGGT1BPTGS1GSTK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| US-12297472-B2 | Split inteins with exceptional splicing activity | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2025-05-13 | — | — | US | disclosed |
| EP-4251210-B1 | MULTI-SPECIFIC HUMAN ALBUMIN NANOPARTICLES DECORATED WITH ANTIBODY FRAGMENTS AND LOADED WITH CYTOTOXICS | ANBITION S R L (IT) | 2025-03-19 | — | — | EP | disclosed |
| EP-4251211-B1 | USE OF MULTI-SPECIFIC HUMAN ALBUMIN NANOPARTICLES DECORATED WITH ANTIBODY FRAGMENTS AND LOADED WITH CYTOTOXIC DRUGS | ANBITION S R L (IT) | 2025-02-26 | — | — | EP | disclosed |
| US-12054541-B2 | Split inteins, conjugates and uses thereof | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2024-08-06 | — | — | US | disclosed |
| US-20240076314-A1 | PEPTIDE COMPOSITIONS AND METHODS FOR INHIBITING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | GLO PHARMA, INC. | 2024-03-07 | — | — | US | disclosed |
| US-20240000967-A1 | USE OF MULTI-SPECIFIC HUMAN ALBUMIN NANOPARTICLES DECORATED WITH ANTIBODY FRAGMENTS AND LOADED WITH CYTOTOXICS | ANBITION S.R.L. (IT) | 2024-01-04 | — | — | US | disclosed |
| US-20230414772-A1 | MULTI-SPECIFIC HUMAN ALBUMIN NANOPARTICLES DECORATED WITH ANTIBODY FRAGMENTS AND LOADED WITH CYTOTOXICS | ANBITION S.R.L. (IT) | 2023-12-28 | — | — | US | disclosed |
| CN-117042807-A | Multispecific human albumin nanoparticles modified with antibody fragments and loaded with cytotoxic drugs | 安必圣有限责任公司 | 2023-11-10 | — | — | CN | disclosed |
| EP-4251210-A1 | MULTI-SPECIFIC HUMAN ALBUMIN NANOPARTICLES DECORATED WITH ANTIBODY FRAGMENTS AND LOADED WITH CYTOTOXICS | Anbition S.r.l. (IT) | 2023-10-04 | — | — | EP | disclosed |
| EP-4251211-A1 | USE OF MULTI-SPECIFIC HUMAN ALBUMIN NANOPARTICLES DECORATED WITH ANTIBODY FRAGMENTS AND LOADED WITH CYTOTOXICS | Anbition S.r.l. (IT) | 2023-10-04 | — | — | EP | disclosed |
| EP-4234689-A2 | SPLIT INTEINS WITH EXCEPTIONAL SPLICING ACTIVITY | The Trustees of Princeton University (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4219549-A1 | SPLIT INTEINS, CONJUGATES AND USES THEREOF | The Trustees of Princeton University (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3408292-B1 | SPLIT INTEINS WITH EXCEPTIONAL SPLICING ACTIVITY | UNIV PRINCETON (US) | 2023-04-26 | — | — | EP | disclosed |
| EP-3431497-B1 | SPLIT INTEINS, CONJUGATES AND USES THEREOF | UNIV PRINCETON (US) | 2022-07-27 | — | — | EP | disclosed |
| WO-2022112866-A1 | USE OF MULTI-SPECIFIC HUMAN ALBUMIN NANOPARTICLES DECORATED WITH ANTIBODY FRAGMENTS AND LOADED WITH CYTOTOXICS | ANBITION S.R.L. (IT) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022112865-A1 | MULTI-SPECIFIC HUMAN ALBUMIN NANOPARTICLES DECORATED WITH ANTIBODY FRAGMENTS AND LOADED WITH CYTOTOXICS | ANBITION S.R.L. (IT) | 2022-06-02 | — | — | WO | disclosed |
| US-20220098293-A1 | SPLIT INTEINS, CONJUGATES AND USES THEREOF | THE TRUSTEES OF PRINCETON UNIVERSITY | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12297472-B2 | Split inteins with exceptional splicing activity | RTCB, NUDT21, RBM17 | FNTA 1046/4885FNTB 1190/4885PGGT1B 2653/4885 |
| US-20230414772-A1 | MULTI-SPECIFIC HUMAN ALBUMIN NANOPARTICLES DECORATED WITH ANTIBODY FRAGMENTS AND LOADED WITH CYTOTOXICS | ALB, ASNS, ENPEP | FNTA 1015/4885FNTB 886/4885PGGT1B 3391/4885 |
| US-20240076314-A1 | PEPTIDE COMPOSITIONS AND METHODS FOR INHIBITING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | CHRNB1, CHRNG, CHRNA1 | FNTA 1788/4885FNTB 1527/4885PGGT1B 1462/4885 |
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | FNTA 445/4885FNTB 837/4885PGGT1B 2074/4885 |
| US-20240000967-A1 | USE OF MULTI-SPECIFIC HUMAN ALBUMIN NANOPARTICLES DECORATED WITH ANTIBODY FRAGMENTS AND LOADED WITH CYTOTOXICS | ALB, CD63, ENPEP | FNTA 598/4885FNTB 1159/4885PGGT1B 2187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.